Novartis’ cholesterol med Leqvio wins EU approval
14th December 2020
Swiss pharma company Novartis’ cholesterol-lowering drug Leqvio (inclisiran) has been granted approval from the European Commission (EC) for the treatment of primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidaemia.
Leqvio has been indicated for use in these populations, which are both characterised by elevated levels of cholesterol, as an adjunct to diet, in combination with a statin or alongside a statin with other lipid-lowering therapies.
The drug can also be administered alone or in combination with other lipid-lowering therapies in patients who are statin intolerant.
Following the EC approval and upon further approval from the UK’s National Institute for Health and Care Excellence (NICE), Novartis and the NHS will make the medicine available through a population-level agreement to reduce the risk of heart disease.
Chapter 5: The Manufacture of Childhood Depression (Part 2) madinamerica.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from madinamerica.com Daily Mail and Mail on Sunday newspapers.
Alunbrig scores NICE backing for ALK-positive lung cancer
11th December 2020
Takeda’s Alunbrig (brigatinib) has been recommended by the UK’s National Institute for Health and Care Excellence (NICE) for patients with ALK-positive advanced non-small cell lung cancer (NSCLC).
Although ALK-positive NSCLC is rare, it is a particularly resistant disease which mainly affects younger people and non-smokers.
Although a number of ALK inhibitors have recently been introduced to this therapy area in recent years, some patients still progress within two to three years of starting treatment. In addition, up to 75% of patients develop brain metastases during the course of their disease.